Compartmentalization and persistence of dominant (regulatory) T cell clones indicates antigen skewing in juvenile idiopathic arthritis

  1. Gerdien Mijnheer
  2. Nila Hendrika Servaas
  3. Jing Yao Leong
  4. Arjan Boltjes
  5. Eric Spierings
  6. Phyllis Chen
  7. Liyun Lai
  8. Alessandra Petrelli
  9. Sebastiaan Vastert
  10. Rob J de Boer
  11. Salvatore Albani
  12. Aridaman Pandit  Is a corresponding author
  13. Femke van Wijk  Is a corresponding author
  1. University Medical Center Utrecht, Netherlands
  2. SingHealth Duke-NUS Academic Medical Centre, Singapore
  3. Utrecht University, Netherlands

Abstract

Autoimmune inflammation is characterized by tissue infiltration and expansion of antigen-specific T cells. Although this inflammation is often limited to specific target tissues, it remains yet to be explored whether distinct affected sites are infiltrated with the same, persistent T cell clones. Here we performed CyTOF analysis and T cell receptor (TCR) sequencing to study immune cell composition and (hyper-)expansion of circulating and joint-derived Tregs and non-Tregs in Juvenile Idiopathic Arthritis (JIA). We studied different joints affected at the same time, as well as over the course of relapsing-remitting disease. We found that the composition and functional characteristics of immune infiltrates are strikingly similar between joints within one patient, and observed a strong overlap between dominant T cell clones, especially Treg, of which some could also be detected in circulation and persisted over the course of relapsing remitting disease. Moreover, these T cell clones were characterized by a high degree of sequence similarity, indicating the presence of TCR clusters responding to the same antigens. These data suggest that in localized autoimmune disease there is auto-antigen driven expansion of both Teffector and Treg clones, that are highly persistent and are (re)circulating. These dominant clones might represent interesting therapeutic targets.

Data availability

TCR-sequencing data presented in this study have been deposited in NCBI's Gene Expression Omnibus (GEO) database under GSE196301. Both raw data and processed data are available.

The following data sets were generated

Article and author information

Author details

  1. Gerdien Mijnheer

    Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  2. Nila Hendrika Servaas

    Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9825-7554
  3. Jing Yao Leong

    Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  4. Arjan Boltjes

    Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  5. Eric Spierings

    Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9441-1019
  6. Phyllis Chen

    Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  7. Liyun Lai

    Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  8. Alessandra Petrelli

    Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  9. Sebastiaan Vastert

    Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  10. Rob J de Boer

    Theoretical Biology, Utrecht University, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2130-691X
  11. Salvatore Albani

    Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  12. Aridaman Pandit

    Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
    For correspondence
    A.Pandit@umcutrecht.nl
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2057-9737
  13. Femke van Wijk

    Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
    For correspondence
    F.vanWijk@umcutrecht.nl
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8343-1356

Funding

ZonMw (91714332)

  • Femke van Wijk

Netherlands Organisation for Scientific Research (016.Veni.178.027)

  • Aridaman Pandit

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Di Chen, Chinese Academy of Sciences, China

Ethics

Human subjects: Informed consent was obtained from all patients either directly or from parents/guardians when the patients were younger than 12 years of age. The study was conducted in accordance with the Institutional Review Board of the University Medical Center Utrecht (approval no. 11-499/C), in compliance with the Declaration of Helsinki.

Version history

  1. Preprint posted: February 10, 2022 (view preprint)
  2. Received: March 29, 2022
  3. Accepted: January 20, 2023
  4. Accepted Manuscript published: January 23, 2023 (version 1)
  5. Version of Record published: March 8, 2023 (version 2)

Copyright

© 2023, Mijnheer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 977
    views
  • 184
    downloads
  • 5
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gerdien Mijnheer
  2. Nila Hendrika Servaas
  3. Jing Yao Leong
  4. Arjan Boltjes
  5. Eric Spierings
  6. Phyllis Chen
  7. Liyun Lai
  8. Alessandra Petrelli
  9. Sebastiaan Vastert
  10. Rob J de Boer
  11. Salvatore Albani
  12. Aridaman Pandit
  13. Femke van Wijk
(2023)
Compartmentalization and persistence of dominant (regulatory) T cell clones indicates antigen skewing in juvenile idiopathic arthritis
eLife 12:e79016.
https://doi.org/10.7554/eLife.79016

Share this article

https://doi.org/10.7554/eLife.79016

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Kevin Portmann, Aline Linder, Klaus Eyer
    Research Article

    Cytokine polyfunctionality is a well-established concept in immune cells, especially T cells, and their ability to concurrently produce multiple cytokines has been associated with better immunological disease control and subsequent effectiveness during infection and disease. To date, only little is known about the secretion dynamics of those cells, masked by the widespread deployment of mainly time-integrated endpoint measurement techniques that do not easily differentiate between concurrent and sequential secretion. Here, we employed a single-cell microfluidic platform capable of resolving the secretion dynamics of individual PBMCs. To study the dynamics of poly-cytokine secretion, as well as the dynamics of concurrent and sequential polyfunctionality, we analyzed the response at different time points after ex vivo activation. First, we observed the simultaneous secretion of cytokines over the measurement time for most stimulants in a subpopulation of cells only. Second, polyfunctionality generally decreased with prolonged stimulation times and revealed no correlation with the concentration of secreted cytokines in response to stimulation. However, we observed a general trend towards higher cytokine secretion in polyfunctional cells, with their secretion dynamics being distinctly different from mono-cytokine-secreting cells. This study provided insights into the distinct secretion behavior of heterogenous cell populations after stimulation with well-described agents and such a system could provide a better understanding of various immune dynamics in therapy and disease.

    1. Immunology and Inflammation
    2. Medicine
    Joanna C Porter, Jamie Inshaw ... Venizelos Papayannopoulos
    Research Article

    Background:

    Prinflammatory extracellular chromatin from neutrophil extracellular traps (NETs) and other cellular sources is found in COVID-19 patients and may promote pathology. We determined whether pulmonary administration of the endonuclease dornase alfa reduced systemic inflammation by clearing extracellular chromatin.

    Methods:

    Eligible patients were randomized (3:1) to the best available care including dexamethasone (R-BAC) or to BAC with twice-daily nebulized dornase alfa (R-BAC + DA) for seven days or until discharge. A 2:1 ratio of matched contemporary controls (CC-BAC) provided additional comparators. The primary endpoint was the improvement in C-reactive protein (CRP) over time, analyzed using a repeated-measures mixed model, adjusted for baseline factors.

    Results:

    We recruited 39 evaluable participants: 30 randomized to dornase alfa (R-BAC +DA), 9 randomized to BAC (R-BAC), and included 60 CC-BAC participants. Dornase alfa was well tolerated and reduced CRP by 33% compared to the combined BAC groups (T-BAC). Least squares (LS) mean post-dexamethasone CRP fell from 101.9 mg/L to 23.23 mg/L in R-BAC +DA participants versus a 99.5 mg/L to 34.82 mg/L reduction in the T-BAC group at 7 days; p=0.01. The anti-inflammatory effect of dornase alfa was further confirmed with subgroup and sensitivity analyses on randomised participants only, mitigating potential biases associated with the use of CC-BAC participants. Dornase alfa increased live discharge rates by 63% (HR 1.63, 95% CI 1.01–2.61, p=0.03), increased lymphocyte counts (LS mean: 1.08 vs 0.87, p=0.02) and reduced circulating cf-DNA and the coagulopathy marker D-dimer (LS mean: 570.78 vs 1656.96 μg/mL, p=0.004).

    Conclusions:

    Dornase alfa reduces pathogenic inflammation in COVID-19 pneumonia, demonstrating the benefit of cost-effective therapies that target extracellular chromatin.

    Funding:

    LifeArc, Breathing Matters, The Francis Crick Institute (CRUK, Medical Research Council, Wellcome Trust).

    Clinical trial number:

    NCT04359654.